Compared to normal melanocytes, melanoma cell lines exhibit overexpression of hyperphosphorylated retinoblastoma tumor suppressor protein (Rb) or a marked decrease in, or lack of, expression of Rb. Hyperphosphorylation of Rb results in increased E2F-mediated transactivation of target genes and cell cycle progression. Using a combination of gene disruption and ectopic expression in growth factor-dependent mouse melanocytes, we studied the roles of E2F1 and the p16 INK4A and p21 WAF1/CIP1 CKIs (cyclin dependent kinase inhibitors) in the acquisition of TPA (12-O-tetradecanoyl phorbol-13-acetate)-independent growth in culture, a hallmark of melanomas. Surprisingly, melanocytes from p16
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-null mice remained TPA-dependent, and disruption of p21 WAF1/CIP1 accelerated cell death in the absence of this mitogen. Disruption of E2F1 had the most profound eect on melanocyte growth, resulting in a fourfold decrease in growth rate in the presence of TPA. Furthermore, enforced overexpression of the DNA-binding-defective E2F1 E132 mutant conferred TPAindependence upon melanocytes and was associated with sequestration of Rb and constitutive expression of E2F1 target genes, including p21 WAF1/CIP1
. We conclude that neutralization of Rb by E2F1 E132 , but not the disruption of p16 INK4A or p21
WAF1/CIP1
Introduction A critical step in the malignant transformation of melanocytes is the acquired ability to proliferate in vitro in the absence of exogenous growth factors. Normal human melanocytes, unlike melanoma cells from advanced lesions, require synergistically-acting mitogenic peptides in addition to serum growth factors in order to survive and proliferate in culture (Halaban, 1996) . Although the precise molecular processes leading to transformation of normal melanocytes to melanomas
have not yet been identi®ed, common genetic lesions and altered gene expression have been implicated. Disruption or inactivation of INK4A (also known as CDKN2, CDK4I and MTS1), which encodes p16
INK4A
, a negative regulator of cyclin dependent kinases 4 and 6 (CDK4 and CDK6) (Sherr, 1996) , has been implicated in melanomas by several studies. INK4A has been localized to chromosomal band 9p21?p22, a region commonly deleted in familial melanomas (reviewed in Haluska and Housman, 1995) see also (Kamb et al., 1994a,b; Nobori et al., 1994) . Furthermore, inactivating mutations in INK4A have been detected in the germ lines of several individuals from melanoma-prone families (reviewed in Cannon-Albright et al., 1996; see also Gruis et al., 1995a,b; Hussussian et al., 1994; Koh et al., 1995; Liu et al., 1995; Reymond and Brent, 1995) . In addition, a single amino acid substitution (Arginine 24 to Cysteine) in CDK4 that renders it resistant to inhibition by p16 INK4A was detected in two out of 23 melanoma cell lines studied Wolfel et al., 1995) , and in the germ lines of individuals from two melanoma pedigrees (Zuo et al., 1996) , but not in patients with sporadic melanomas (Fitzgerald et al., 1996) . Recent reports, however, concluded that the Arg24Cys mutation is rare in melanoma pathogenesis (Flores et al., 1997; Guldberg et al., 1997) , and one study revealed only an additional novel Asn41Ser missense mutation in one tumor (Guldberg et al., 1997) . The notion that unregulated CDK activity can contribute to the malignant transformation of melanocytes was reinforced by the ®nding that expression of p21 WAF1/CIP1 , the CKI which negatively regulates CDK2 and CDK4 is decreased in melanoma cell lines (Jiang et al., 1995) .
The primary substrate of CDK2, CDK4 and CDK6 is the retinoblastoma tumor suppressor protein (Rb) (Taya, 1997; Weinberg, 1996b) . Under normal conditions, Rb undergoes cell cycle-dependent phosphorylation and dephosphorylation that regulate its activity (Ludlow et al., 1993; Ludlow and Nelson, 1995; Weinberg, 1995) . Phosphorylation of Rb during the mid to late G 1 -phase of the cell cycle is mediated by activated CDK4, CDK6 and CDK2 (DeGregori et al., 1995a; Geng et al., 1996; Jacks and Weinberg, 1996; Nevins, 1992; Ohtani et al., 1995) , whereas dephosphorylation during mitosis and through early G 1 is mediated by protein phosphatase 1 (PP1) (Durfee et al., 1993; Ludlow and Nelson, 1995; Puntoni and VillaMoruzzi, 1997) . Hypophosphorylated Rb associates with transcription factors from the E2F family causing cell cycle arrest (Adams and Sellers et al., 1995; Shan et al., 1996) . Treatment of quiescent cells with mitogenic growth factors leads to phosphorylation and inactivation of Rb by inducing the expression of G 1 /S cyclins, which are positive regulatory subunits required for CDK activity (Pardee, 1989; Sherr, 1995 Sherr, , 1996 Weinberg, 1996b) . Hyperphosphorylated Rb dissociates from E2F, thus stimulating its transactivation activity. E2F activates genes encoding proteins required for cell cycle progression, including dihydrofolate reductase (DHFR), DNA polymerase a, cyclin E, cyclin D1, cyclin A, cdc2, the transcription factors cMyc and B-Myb (for reviews, see Adams and Kaelin, 1996; Schulze et al., 1995; Slansky and Farnham, 1996; Weinberg, 1996a) , as well as p18 INK4C and p19 ARF (DeGregori et al., 1997) . Unrestricted cellular proliferation can result from the constitutive phosphorylation of Rb by deregulated CDK4 Liu et al., 1995 Okamato et al., 1994; Quelle et al., 1995; Walker et al., 1995; Zuo et al., 1996) . In addition, mutations in the Rb`pocket' region (the E2F binding domain) (see for example Horowitz et al., 1989 Horowitz et al., , 1990 , or sequestration of Rb by viral transforming proteins, such as the human papilloma virus E7 protein Munger et al., 1989; Whyte et al., 1988) , the adenovirus E1A protein (Dyson, 1994; Peeper and Zantema, 1993) , or the SV40 large T-antigen (Dyson et al., 1990) , can also contribute to transformation by competitively inhibiting the interaction between Rb and E2F transcription factors.
Inherited mutations in Rb predispose humans to melanoma since retinoblastoma patients and their relatives display an increased risk to develop melanomas as well as other tumors (see for example Bataille et al., 1995; Moll et al., 1997 . However, inactivating mutations in Rb are rare in melanomas Horowitz et al., 1990) . Rather, the function of Rb in these tumors is commonly inhibited by hyperphosphorylation, and to a lesser extent, by underexpression Halaban et al., 1998) . In fact, compared to normal melanocytes, melanoma cell lines exhibit overexpression of hyperphosphorylated Rb (10 of 15 cell lines) or a marked decrease in, or lack of, Rb expression (®ve of 15 cell lines) Halaban et al., 1998) . To better understand the roles of CKIs and E2F1 in melanocyte growth and transformation, we examined the mitogenic response of melanocytes derived from mice with targeted disruptions of either the p16 INK4A , p21
or E2F1 genes and of melanocytes ectopically expressing wild-type or mutated E2F1 alleles. Melanocytes with homozygous disruption of p16 INK4A or p21 WAF1/CIP1 were dependent on, and responded normally to mitogenic stimuli, whereas disruption of E2F1 resulted in a substantially reduced growth rate. Deletion of p21 WAF1/CIP1 or E2F1 caused accelerated death in growth factor-deprived medium. In addition, overexpression of a DNAbinding-defective E2F1 (E2F1 E132 ), which indirectly stimulated endogenous E2F activity by sequestering Rb, conferred mitogen-independent proliferation and drastic changes in morphology upon transfected melanocytes. Surprisingly, p21 WAF1/CIP1 expression was also increased by E2F1 E132 and was associated with the proliferation of melanocytes. Taken together, these data demonstrate that E2F1 plays a central role in melanocyte proliferation and that disruption of either p16 INK4A or p21 WAF1/CIP1 was not sucient to induce E2F-mediated autonomous growth, suggesting that other mechanisms which activate E2F1 may be important in the deregulated growth of melanomas.
Results

p16
INK4A
, but not p21 WAF1/CIP1 or E2F1, is dispensable for viability and normal proliferation of mouse melanocytes To determine whether disruption or p16 INK4A or p21 WAF1/CIP1 aected melanocyte growth in culture, we compared the abilities of pigment cells derived from wild-type, p16 7/7 or p21 7/7 mice to grow and survive in serum-supplemented medium in the presence or absence of TPA, which is required for melanocyte viability and growth in culture (Dotto et al., 1988; Tamura et al., 1987) . Interestingly, cultures of p16
7/7 or wild-type melanocytes each showed growth rates of approximately 2 days PDT (population doubling time) in the presence of TPA and were arrested in its absence (Figure 1a ± c) . However, p21 7/7 melanocytes displayed increased sensitivity to TPA withdrawal (Figure 1c, E132(37) , compare circles to rectangles). In addition, melanocytes overexpressing E2F1 E132 lost their dendritic morphology and became ®broblastic (Figure 2b ). This phenotype was dependent on high E2F1 E132 expression since another clone with low levels expression was phenotypically normal by these measures (data not shown). Cell cycle analysis revealed that the TPAindependent growth of E2F1 E132 -overexpressing cells was re¯ected by their partial resistance to G 1 -arrest normally induced by TPA-deprivation (Figure 2c ). In contrast, transfection with E2F1 wt or E2F1 FS409 encoding plasmids did not lead to changes in melanocyte proliferation, viability or morphology (Figure 2a , and data not shown). The inability of the E2F1 wt transfectants to proliferate under TPA-starved conditions was not the result of poor expression of this ectopic gene compared to the E2F1 E132 , since both early passage (low expressors, Figure 2a , solid circles, and d, compare lane 3 to 5 and 7) and late passage (high expressors, Figure 2a , empty circles, and d, compare lanes 9 and 10) were growth arrested in the absence of TPA. Despite their autonomous growth in culture, the E2F1 E132(37) cell line, like the control and E2F1 wt transfectants, did not form tumors in syngeneic or nude mice, indicating that additional events are needed to confer tumorigenicity.
Since E2F1 is known to be degraded by the proteasome (Campanero and Flemington, 1997; Hateboer et al., 1996; Hofmann et al., 1996) , we examined whether the elevated steady state expression of E2F1 E132 and E2F1 FS409 compared to E2F1 wt in early passage cells could be explained by their resistance to proteasome-mediated degradation. Incubation with the proteasome inhibitor MG132 (Coux et al., 1996) caused a similar accumulation of each E2F1 protein (relative to non-treated controls), indicating that the dierences in steady state expression between E2F1 wt , E2F1 E132 and E2F1 FS409 were not due to dierential sensitivity to degradation by the proteasome complex ( Figure 2d , lanes 3 ± 8). E2F1 wt and E2F1 E132 appeared as multiple bands in the range of 50 ± 60 kDa ( Figure  2d lanes 3 ± 6, 9 and 10 bracket) probably due to heterogeneously phosphorylated E2F1 species (Peeper et al., 1995; Yang and Sladek, 1997) . In contrast, E2F1 FS409 migrated as a *50 kDa protein (Figure 2d , lanes 7 and 8). This result was expected, since the frame-shift-induced scrambled amino acid sequence near the carboxyl terminus of E2F1 FS409 Johnson et al., 1993) eliminated several CDK phosphorylation sites (Slansky and Farnham, 1996) . The high molecular weight forms of E2F1 induced by MG132 (Figure 2d , lanes 6 and 8, arrow) are probably the result of covalently bound multi-ubiquitin (Campanero and Flemington, 1997; Hateboer et al., 1996; Hofmann et al., 1996) . The 60 kDa and 45 kDa proteins detected by the anti-E2F1 antibody ( Figure  2d , arrowheads) were nonspeci®c, since they were also present in melanocytes from E2F1 7/7 mice ( Figure 2d , lane 11). Together, these results indicated that overexpression of the DNA-binding-defective E2F1 E132 protein in mouse melanocytes dramatically altered the growth characteristics and morphology of murine melanocytes in culture.
E2F1 proteins associated with Rb
To further examine the properties of ectopic E2F1 proteins in melanocytes, we compared the abilities of E2F1 wt and E2F1 E132 to interact with Rb in both GST-Rb pulldown'-and anti-E2F1 co-immunoprecipitation assays. The results con®rmed that both E2F1 wt and E2F1 E132 were competent to associate with Rb ( Figure 3a and b). The association between E2F1 E132 and Rb was more evident (Figure 3a Figure 3b ). Interestingly, an additional 105 kDa Rb band, that migrated faster than the hypophosphorylated *106 kDa Rb, was apparent in complex with E2F1 E132 and in whole cell lysates of E2F1 E132(37) melanocytes, but not in the other cell extracts (Figure 3b and c, bands marked Rb). This band probably represents unphosphorylated Rb bound to E2F1 E132 . This notion is supported by the observation that TPA starvation induced the accumulation of the 106 kDa Rb species in a time dependent manner in each melanocyte cell line, whereas the intensity of the 105 kDa form of Rb did not change ( Figure 3c , compare bands marked pRb to Rb). Due to its low-level expression, Rb was dicult to detect in whole cell extracts of these cells using conventional immunoblotting (Figure 3c ). Thus, we further investigated the status of Rb by immunoblotting Rb immunoprecipitates. Compared to vector-transfected melanocytes, E2F1 E132 -expressing melanocytes contained signi®cantly elevated amounts of hyperphosphorylated Rb, regardless of cultured conditions ( Figure 3d compare lanes 1 ± 4 to 5 ± 8). Furthermore, E2F1 E132 melanocytes expressed an increased amount of total Rb, which is consistent with its increased participation in E2F1-Rb complexes in these cells (Figure 3b, E2F1 E132(37) ). The slowly migrating (hyperphosphorylated) form of Rb seen 8 h after TPA stimulation of vector-transfected melanocytes was rapidly converted to a higher mobility (hypophosphorylated) form that was also predominant in exponentially growing cells (Figure 3d compare lane 3 to 1 and lanes 2 and 4). This result is consistent with the slight variation in the amount of Rb detected in association with E2F1 in these cells (Figure 3b, vector) . Together, these data indicated that both E2F1 wt and E2F1 E132 interacted with Rb, but that expression of E2F1 E132 also resulted in an upregulation of total Rb expression and consequently an increase in the amount of E2F1 E132 -Rb complex formation. Thus, chronic high-level expression of E2F1 E132 in transfected melanocytes appeared to result in the sequestration and inactivation of Rb.
Endogenous E2F activity was enhanced by expression of E2F1 E132
We next investigated whether the partially transformed phenotype of transfected melanocytes induced by E2F1 E132 was associated with an increase in endogenous E2F-mediated transcriptional activity. Transient transfection assays using a luciferase reporter plasmid containing the E2F-responsive human DHFR promoter (7), or with 50 mM MG132 for 6 h (+). Lanes 9 and 10 represent melanocytes from late passage (p35) transfectants. Lane 11 was loaded with lysate from E2F1 7/7 melanocytes. Arrows point at E2F1 proteins and arrowhead at non-speci®c bands. The intensity of these none speci®c binding proteins can serve as a measure for protein loading. Positions of prestained molecular weight markers (Bio-Rad) are given on the left in kDa with either a wild-type or mutated E2F response element, showed that E2F-stimulated DHFR promoter activity was two to fourfold higher in E2F1 E132 -overexpressing melanocytes than in control or early passage E2F1 wt transfectants (Figure 4a ). In contrast, equivalent amounts of luciferase activity were detected in lysates from each cell line transfected with the E2F-unresponsive pGL3-CONTROL promoter-reporter plasmid (data not shown). In addition, comparison of luciferase activities generated in the presence or absence of TPA in each cell line showed that the human DHFR promoter was only marginally regulated by TPA (Figure 4a ). To determine whether the increased E2F1 E132 -mediated transcriptional activity was associated with increased E2F DNA-binding activity, we employed the electrophoretic mobility shift assay (EMSA) to test nuclear extracts from vector-transfected and E2F1 E132 -transfected melanocytes for binding activity to a double-stranded oligodeoxynucleotide containing a consensus E2F binding site (see for example Johnson et al. (1994) ). We detected a dramatic increase in E2F DNA binding activity in E2F1 E132 -transfected melanocytes compared to vector-transfected cells (Figure 4b , compare lanes 4 and 5 to lanes 2 and 3). The interaction was eectively competed by unlabeled homologous oligodeoxynucleotide at a 50-fold molar excess (Figure 4b , lane 6), but not by a 100-fold molar excess of a heterologous oligodeoxynucleotide containing a consensus binding site for the c-Myb transcription factor (Figure 4b, lane 9) . A similar experiment employing nuclear extract from late passage melanocytes expressing high levels of E2F1 wt showed E2F DNA binding activity similar to that of vectortransfected cells (data not shown), suggesting that the ectopic E2F1 is either not transported to the nucleus or is not competent to recognize the E2F consensus binding site in vitro.
To con®rm whether the increase in endogenous E2F DNA-binding and transactivating activities observed in E2F1 E132 cells was corroborated by increased expression of a known E2F1-responsive gene, we analysed cyclin D1 expression in exponentially growing or TPA starved control, early passage E2F1 wt(2) and E2F1 E132(37) melanocyte cell lines. As expected, cyclin D1 levels declined in TPA-deprived control and E2F1 wt(2) melanocyte cell lines (Figure 4c , cyclin D1). In contrast, cyclin D1 remained highly expressed in the E2F1 E132(37) melanocyte line under TPA-deprived conditions (Figure 4c , cyclin D1), whereas expression of cyclin E remained constant in proliferating and arrested cells (data not shown). Detection of CDK2, which was not modulated by expression of E2F1 E132(37) , served as a control for equal loading (Figure 4c , CDK2). These results indicated that ectopic expression of the DNA-binding-defective E2F1 E132 protein in mouse melanocytes resulted in increased E2F DNAbinding activity and E2F-mediated transactivation and are consistent with E2F1 E132 sequestering Rb and releasing active endogenous E2F proteins.
We next examined whether TPA-independent growth of E2F1 E132(37) melanocytes was re¯ected by additional changes in expression of cyclin A (another known E2F1-responsive gene) and the p27 KIP1 , p21 WAF1/CIP1 , and p16 INK4A CKIs. TPA-starved melanocytes were restimulated and examined at various time points for cyclin A and CKI expression, and for progression through the cell cycle. Immunoblot analysis showed a dramatic induction of cyclin A expression in control (vector) melanocytes 24 h after TPA-stimulation (Figure 5a, cyclin A) . In contrast, cyclin A expression was signi®cantly elevated in the E2F1 E132(37) cell line and was additionally upregulated 16 ± 24 h after TPA treatment (Figure 5a , cyclin A). For both cell lines, maximal cyclin A expression correlated with mid S phase as determined by incorporation of tritiated thymidine (Figure 5a , compare cyclin A with 3 H-dT Incorporation). Among the three CKIs tested, only p27 KIP1 exhibited the expected pattern of expression by decreasing after mitogenic stimulation, and by being less abundant in E2F1 E132(37) cells compared to control melanocytes (Figure 5a, p27) . Surprisingly, slight increases in p16
INK4A expression correlated with cellular proliferation in control and E2F1 E132(37) melanocytes (Figure 5a,  p16) . Consistent with our ®nding that p21 WAF1/CIP1 was Each data point represents fold induction over mutant control and is an average of two experiments in which triplicate dishes were used per transfection condition, and three measurements were performed/dish. (b) E2F1 E132 -induced DNA-binding activity toward an E2F recognition sequence. Nuclear extracts from vector-transfected and E2F1 E132 -transfected melanocytes were assayed for their ability to associate with an E2F binding site by EMSA. Lane 1, free probe; lane 2, TPA-deprived (24 h) vector transfectants; lane 3, vector transfectants restimulated with TPA for 3 h; lane 4, TPA-deprived (36 h) E2F1 E132 -transfectants; lane 5, E2F1 E132 -transfectants restimulated with TPA for 3 h; lane 6, competition experiment using TPA-stimulated E2F1 E132 extracts and 50-fold molar excess of unlabeled E2F oligodeoxynucleotide; lane 7, competition experiment using 100-fold excess of unlabeled E2F oligodeoxynucleotide; lane 8, competition experiment using 50-fold molar excess of unlabeled Myb binding site (MBS) oligdeoxynucleotide; lane 9, competition experiment using 100-fold molar excess of unlabeled MBS oligodeoxynucleotide. (c) E2F1 E132 induced constitituve expression of cyclin D1. Western blots of extracts derived from exponentially growing (+), or 24 h TPA-starved (7) melanocytes. The same membrane was probed with antibodies to cyclin D1 or CDK2, as indicated required for melanocyte viability (Figure 1c) , elevated p21 WAF1/CIP1 expression was associated with cell cycle progression rather than with growth arrest (Figure 5a functioned normally with respect to its ability to bind CDK2 and CDK4 in coprecipitation assays (Figure 5d ). Taken together, these data indicated that accumulation of p27 KIP1 , and not p21 WAF1/CIP1 or p16
INK4A
, was associated with growth arrest in response to TPA withdrawal, and that mitogen-induced p21 WAF1/CIP1 or p16 INK4A did not interfere with cell cycle progression.
E2F1 E132 induced p21 WAF1/CIP1 expression pretranslationally
To determine the level at which p21 WAF1/CIP1 expression was upregulated in growth factor-stimulated normal melanocytes, and in the E2F1 E132(37) melanocyte line, we ®rst examined the possibility that TPA treatment or expression of E2F1 E132 resulted in the stabilization of p21
, since this CKI is known to be the target for degradation by the proteasome (Maki and Howley, 1997) . Treatment with the proteasome inhibitor MG132 did not cause a marked accumulation of p21 WAF1/CIP1 in either control or E2F1 E132 melanocytes in the presence or absence of TPA, indicating that the increased expression of p21 WAF1/CIP1 in E2F1 E132(37) cells was not due to decreased proteasome-mediated degradation (Figure 6a) . Furthermore, treatment with the protein synthesis inhibitor cycloheximide indicated WAF1/CIP1 associated with CDK2 and CDK4. Cell extracts (250 mg protein/reaction) prepared from exponentially growing melanocytes (+) or from cultures that had been TPA-deprived for 8 h (CDK2), or 12 h (CDK4), were subjected to immunoprecipitation (IP) with CDK2, CDK4 or control antibodies (IgG). The absorbed complexes were Western blotted with anti-p21 antibodies WAF1/CIP1 antibodies of cell extracts from 24 h starved (7) or exponentially proliferating (+) melanocytes that had been treated with the proteasome inhibitor MG132 (50 mM) for the indicated duration before harvest. (b) TPA and E2F1 E132 induced p21 WAF1/ CIP1 mRNA, but the levels of transcripts did not correlate with protein levels. Quantitative RT ± PCR using mRNA extracted from starved (7), or starved and TPA (6 h) stimulated (+) melanocytes using primers speci®c for p21 WAF1/CIP1 or cyclophilin (as indicated). Input cDNA was at 16 or 0.16 concentrations as indicated that p21 WAF1/CIP1 expression decayed at a similar rate in the two cell lines grown with or without TPA (data not shown). These results suggested that p21 WAF1/CIP1 expression was not regulated post-translationally by TPA or by overexpression of E2F1 E132 in mouse melanocytes.
To determine whether p21 WAF1/CIP1 mRNA levels were regulated by TPA or by E2F1 E132 overexpression, we compared steady state amounts of p21 WAF1/CIP1 mRNA in control and E2F1 E132(37) melanocytes using RT ± PCR (Figure 6b) . Expression of p21 WAF1/CIP1 mRNA was clearly upregulated by TPA in control cells (Figure 6a,  vector) . In contrast, E2F1 E132(37) melanocytes expressed similarly elevated amounts of p21 WAF1/CIP1 mRNA in the absence or presence of TPA (Figure 6b, E2F1 E132(37) ). These data indicated that the increased expression of p21 WAF1/CIP1 was mediated, at least in part, pretranslationally by expression of E2F1 E132 in mouse melanocytes.
Discussion
We have demonstrated critical roles for Rb sequestration and E2F activity in melanocyte proliferation. A positive correlation was observed between the number of intact E2F1 alleles and rate of proliferation in response to TPA. Moreover, ectopic expression of the DNA-binding defective E2F1 E132 mutant in mouse melanocytes induced a partially transformed phenotype by conferring growth-factor-independent cell cycle progression and drastic changes in cellular morphology. Partial transformation of melanocytes was contingent upon high levels of ectopic E2F1 E132 and was not reproduced in melanocytes expressing similarly high levels of ectopic wild-type E2F1, since those cells still required TPA for proliferation. It is possible that high levels of wild-type E2F1 may induce apoptosis. Indeed, this phenomenon has been observed in transfected ®broblasts (Adams and Hiebert et al., 1995; Phillips et al., 1997; Schulze et al., 1995; Slansky and Farnham, 1996; Weinberg, 1996a) . In fact, defects in E2F1-mediated apoptosis in combination with a loss of the E2F1-Rb repressor function probably jointly contribute to tumor development in E2F1 7/7 mice, which has led to the realization that E2F1 can function as both an oncogene and as a tumor suppressor gene (Field et al., 1996; Yamasaki et al., 1996) , see comment (Weinberg, 1996a) . The results generated from E2F1 E132 expression were unexpected, because previous studies employed this mutant as a negative control for wild-type E2F1 activity in transient assays (DeGregori et al., 1995b; Kowalik et al., 1995) . Moreover, in long term assays, wild type DNAbinding and Rb-binding activities were required by E2F1 for oncogenic transformation of rat embryo ®broblasts (Singh et al., 1994) . However, it should be noted that the acquisition of TPA-independent growth by melanocytes represents only one step in the transformation pathway, and that E2F1 E132 overexpressing cells did not grow as tumors in either syngeneic or nude mice. Therefore, it is inappropriate to compare melanocytes to ®broblasts, which proliferate in culture in standard serum-supplemented medium and do not require any additional factors, such as TPA. E2F1 E132 appeared to mediate its eects, in part, by sequestering Rb and freeing endogenous E2F1 to stimulate cell cycle progression. This notion is supported by several ®ndings. First, E2F1 E132 was readily detected in association with Rb in GSTpulldown and co-immunoprecipitation assays. Second, expression of E2F1 E132 in mouse melanocytes induced E2F-mediated transactivation of the DHFR promoter and E2F DNA-binding activity. These activities were not mediated directly by E2F1 E132 , since it cannot bind DNA. Lastly, E2F1 E132 induced the expression of cyclin A and cyclin D1, whose genes are known E2F1 targets. Neutralization of Rb by E2F1 E132 could conceivably result in the release and activation of several E2F family members, including E2F1, E2F2, E2F3 and E2F4 (Li et al., 1997; Moberg et al., 1996) . However, the pattern of increased gene expression in our system is most compatible with release of E2F1, since among the ®ve known members, it is particularly ecient in inducing cyclin A, and is a poor activator of CDK2 expression (DeGregori et al., 1997) . However, since Rb binds many dierent proteins in addition to E2F transcription factors, it is possible that E2F1 E132 mediated some of its eects by disrupting the association between Rb and proteins other than E2Fs (reviewed by Taya 1997) .
Induction of p21 WAF1/CIP1 by either TPA or E2F1 E132 under condition of increased cell proliferation was surprising because of its presumed role, based on increased levels, as a cell cycle inhibitor in U.V.B.-irradiated human melanocytes and in melanoma cells which have been growth arrested and induced to dierentiate with interferon-b and the antileukemic compound mezerein (Jiang et al., 1996) . However, our results are consistent with the recent observations of increased expression of immunoreactive p21 WAF1/CIP1 in human melanoma tumors (Maelandsmo et al., 1996; Trotter et al., 1997) . In one report, immunohistochemistry staining of a set of common acquired nevi, dysplastic nevi, primary and metastatic melanomas showed that p21 WAF1/CIP1 levels positively correlated with the proliferation marker Ki67, indicating that the CKI was present also in cycling cells at levels not sucient to induce growth arrest (Trotter et al., 1997) .
Other examples of upregulated p21 WAF1/CIP1 expression following mitogenic stimuli, include mouse ®broblasts responding to serum factors (Macleod et al., 1995) , and M07e myeloid cells responding to synergistic growth factors (Mantel et al., 1996) . Activation of p21 WAF1/CIP1 expression during mitogenic stimulation is probably mediated by mitogen-activated protein kinase signaling (MAPK) (Liu et al., 1996) . It has been suggested that p21 WAF1/CIP1 may function as either a positive or negative regulator of the cell cycle, depending on its concentration within the cell. p21 WAF1/ CIP1 exists in quaternary complexes with PCNA, cyclin, and CDK in both catalytically active and inactive forms (Zhang et al., 1994) . p21 WAF1/CIP1 also facilitates the interaction between cyclin D1 and CDK4, in some cases displacing p27 KIP1 from CDK4 and cyclin D1 ternary complexes, with concomitant increase in cyclin D1-associated kinase activity and stimulation of cell cycle progression (see for example LaBaer et al. 1997; Mantel et al. 1996) . However, it should be noted that a positive role for p21 WAF1/CIP1 in melanocyte viability was observed only under starved conditions, since p21 WAF1/ CIP1 -null melanocytes quickly died after TPA withdrawal, but remained responsive to the phorbol ester and appeared normally dierentiated, as judged by melanin production and dendritic morphology (data not shown). Thus, in spite of its possible role as à matchmaker' between CDK and cyclin, p21 WAF1/CIP1 is not required for normal mitogen-driven melanocyte proliferation.
Homozygous disruption of p16 INK4A did not override the G 1 block induced by TPA deprivation, nor did it impact upon proliferation or dierentiation. These results are consistent with the notable absence of melanomas among the spontaneous tumors developed at an early age in p16 INK4A knockout mice (Serrano et al., 1996) . Furthermore, several studies have shown that absence of p16
INK4A was not strictly correlated with malignant transformation of human melanocytes. For example, p16
INK4A deletions were detected in 1/3 of normal human melanocyte isolates and in 8/8 benign compound nevi (Wang and Becker, 1996) . In addition, it has been suggested that p16
INK4A does not play a major role in melanomas since the incidence of diseaseassociated missense mutations in p16
INK4A in some of the melanoma pedigrees was extremely low (Wainwright, 1994) , (reviewed by Haluska and Housman, 1995) , and the frequency of mutation in p16
INK4A in cases of sporadic cutaneous melanoma (of which most demonstrated loss of heterozygosity at 9p21) was also low (18% at most) (Fitzgerald et al., 1996; Healy et al., 1996) . In fact, another study failed to detect homozygous deletion of p16 INK4A in any of the cutaneous melanoma tumors in spite of loss of heterozygosity for 9p (Puig et al., 1995) .
Melanomas, as well as several other cancers, are believed to achieve autonomous growth in part by activating the expression of endogenous, autocrineacting growth factors, such as basic ®broblast growth factor (bFGF or FGF-2), reviewed by (Halaban, 1996) . Such mitogenic growth factors are known to stimulate the expression of cyclin D1, which positively regulates CDK4 and CDK6 activity and cell cycle progression Sherr, 1996; Wang et al., 1997) . The results described in this report support a model in which activated endogenous growth factor production and defects in CKIs or activating mutations in CDK4 collaborate to neutralize Rb, which ultimately results in deregulated E2F activity and autonomous growth of melanoma cells. Indeed, neutralization of Rb by hyperphosphorylation appears to be common in melanoma cell lines Halaban et al., 1998) .
Materials and methods
Culture conditions, expression plasmids, transfection and cloning
Wild-type melanocytes (from B10.BR mice, Jackson Laboratory, Bar Harbor, MA) were maintained in basic medium (Ham's F10 containing 200 U/ml penicillin, 100 mg/ml streptomycin and 10% horse serum, all from GibcoBRL Laboratories, Grand Island, NY) supplemented with 85 nM TPA (Sigma Chemical Co., St. Louis, MO) (Tamura et al., 1987) . These melanocytes are stringently dependent on TPA even in the presence of serum and do not grow as tumors in syngeneic or nude mice (Dotto et al., 1989) .
Melanocytes from the skin of newborn knockout mice deleted for p16
INK4A (Serrano et al., 1996) , p21 WAF1/CIP1 (Deng et al., 1995) , or E2F1 (Field et al., 1996) , (obtained from the respective investigators), were grown as described except that the initial basic medium contained (in addition to TPA) 50 m M dbcAMP (N 6 , 2'-dibutytryladenosine 3' : 5'-cyclic monophosphate), 1 mM Na 3 VO 4 (sodium orthovanadate, both from Sigma), and 10% fetal calf serum (GibcoBRL). Pure melanocyte cultures were obtained by subcloning pigmented clones and by selectively killing ®broblasts with 10 mM methotrexate for 2 days. Mouse melanocytes are easily established in culture as immortal cells that no longer require cyclic AMP stimulators or vanadate for proliferation. A genomic PCR assay was performed to genotype all progeny using primers positioned to amplify dierent size fragments of the wild-type versus the mutant allele (as recommended by the respective investigators). In addition, the absence of the gene product was veri®ed by Western blotting.
For permanent transfection, wild-type B10.BR melanocytes at passages 20 ± 25 (approximately 1610 6 /dish) were transfected with 50 mg DNA of each of the E2F1-encoding plasmids along with 5 mg DNA of pSVneo (Biotech Research Laboratories, Rockville, MD) or pRc/CMVneo (Invitrogen, Carlsbad, CA) mammalian expression vectors (conferring geneticin resistant) using the lipofection reagent DOTAP (Boehringer, Mannheim, Germany) following the manufacturer's instructions. The plasmids pCMV-E2F1 wt , a variant pCMV-E2F1 E132 with mutations that inactivate the DNA binding site (two point mutations at positions 132 and 133, where leucine and asparagine have been changed to glutamatic acid and phenylalanine), or a variant pCMV-E2F1 FS409 with frame shift mutation rendering the protein incapable of binding to Rb were from Dr Joseph R Nevins, Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC. Transfections with the empty vectors pSVneo or pRc/CMVneo (designated vector) served as negative controls. Stable cell lines were established after selection in medium supplemented with 400 mg and 800 mg/ml neomycin (G-418 sulfate, GibcoBRL) plus TPA. The number of colonies resistant to G418-sulfate varied between transfection and was two for pCMV-E2F1 wt , *40 for pCMV-E2F1 FS409 , 12 for pCMV-E2F1 E132 , 14 for pCMVneo, and ®ve for pSVneo. We cannot determine the reason for the low eciency of resistant colonies in the E2F1 wt transfectants because selection of stable clones was dependent on the integration of two independent plasmids (pSVneo and pCMV-E2F1 wt ).
Stable clones (2 ± 5) from each transfection were expanded and used for further studies. RT ± PCR analysis showed ampli®cation of the expected size band and con®rmed the expression of the ectopic gene in cells transfected with each of the E2F1-encoding plasmids but not in the vector transfectants. Furthermore, EcoRI digestion of the puri®ed 416 bp ampli®ed segments con®rmed the presence of the EcoRI restriction site in the E2F1 E132 transfectants created by the mutation, that was absent from the control E2F1 wildtype product (data not shown).
Proliferation, cell cycle determination and tumorigenicity assays
For proliferation assays, cells were seeded in 6-well cluster plates (*20 000 cells/well), grown in sets of duplicate or triplicate wells in basic medium with or without TPA and counted in a Coulter counter. Media were renewed every 2 ± 3 days. Population doubling times (PDT) were calculated from the slopes of the linear portions of the growth curves.
For cell cycle analysis, melanocytes were seeded at 60 ± 70% con¯uencey (approximately 1610 6 cells/well in 100 mm Petri dishes), deprived of TPA for 36 h in basic medium and then restimulated with TPA. The cells were harvested at dierent time points (0, 24 and 40 h), stained for DNA content with propidium iodide and analysed employing the¯uorescence cell sorter (Beckton Dickinson). The [ 3 H]thymidine incorporation assay was used to determine the peak of DNA synthesis (Sphase) as described (Funasaka et al., 1992; Halaban et al., 1987) with slight modi®cation. Melanocytes (0.5 ± 1610 6 ) were plated in multi-well plates (12 well plates) in the basic medium in the absence of TPA for 36 h. They were then stimulated with TPA and subsequently pulsed at dierent time points for 1 h with [ 3 H]thymidine (5 mCi/ml) in MEMS medium (minimal essential medium for suspension, GibcoBRL) without serum. Cells were then harvested and radioactivity determined as described (Funasaka et al., 1992; Halaban et al., 1987) . Data are means of triplicate wells.
To assess tumorigenicity, melanocytes were injected subcutaneously (1610 6 cells/injection site) into 4 ± 6 week old syngeneic (B10.BR) or nude mice (The Jackson Laboratory, four mice/cell type). The mice were inspected weekly for tumor growth over a period of 3 months.
Transient transfections, reporter plasmids, and luciferase assays
Melanocytes (approximately 1610 6 cells, at 60 ± 70% con¯uence) were transfected with luciferase reporter plasmid (2 mg DNA/dish) in PC-1 de®ned medium (HYCORE Biomedical Inc., Arvin, CA) without serum (in duplicate or triplicate plates/condition) using the lipofection reagent DOTAP. After overnight incubation, the cells were switched to fresh basic medium (in the presence or absence of TPA, as indicated) for 2 ± 3 days. Melanocytes were harvested and luciferase activity was measured in triplicate (1 mg protein/assay) using the Luciferase Assay System (Promega, Madison, WI) following the manufacturer's instruction with a Bethold Lumat LB9501 luminometer (courtesy of Dr N Berliner of the Yale Medical School Department of Hematology). Protein concentrations were determined by the Bio-Rad Protein Assay kit (Bio-Rad Laboratories, Hercules, CA). The number of cells per treatment was determined on additional two dishes.
The pMae vectors encoding the luciferase gene driven by the DHFR (dihydrofolate reductase) promoter (Slansky et al., 1993) were from Dr P Farnham, McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, Madison, WI. The DHFR promoter contained the region located between 7270 and +20 upstream of the transcription initiating site included the consensus binding site for E2F1 TTTCGCGCCAAA, or a mutant TTTCGatGCCAAA binding sites (nucleotide changes presented in lower case) not responsive to E2F activation; the latter was used as negative control. To evaluate variability between the cell lines in uptake and expression of plasmid DNA we used the PGL3 vector (Promega, Madison, WI) encoding the luciferase gene under the control of the SV40 promoter from which all AP2 sites were removed.
Electrophoretic Mobility Shift Assays (EMSA)
Nuclear extracts from vector-and E2F1 E123 -transfected melanocytes were prepared as described (Dignam et al., 1983) . A double-stranded oligodeoxynucleotide containing a single E2F binding site (Santa Cruz Biotechnology, Santa Cruz, CA) was radiolabeled to a speci®c activity of at least 1.1610 5 c.p.m./ng DNA using T4 polynucleotide kinase (New England Biolabs, Inc., Beverly, MA) with [g-32 P]ATP (DuPont NEN, 6000 Ci/mmole). Unincorporated nucleotides were removed from the reaction using Probe Quant G-50 microspin column (Pharmacia Biotech Inc., Piscataway, NJ) per the manufacturers' instructions. EMSA reactions contained 7 mg nuclear extract, 2 ml 106 buer (®nal concentration: 10 mM Tris-HCl, pH 7.9, 50 mM NaCl, 1 mM EDTA, 0.05% nonfat dry milk, 5% glycerol, 0.01% saturated bromophenol blue), 1 ml dithiothreitol (100 mM, Boehringer Mannheim), 1 ml poly(dI-dC) (1 mg/ml, Sigma), 13 ml H 2 O, 2 ml (approximately 0.2 ng or at least 20 000 c.p.m.) 32 P-labeled probe and were incubated at 278C for 45 min. For competition assays, cell extracts were preincubated with unlabeled competitor oligodeoxynucleotide for 30 min at 278C followed by the addition of labeled probe for an additional 15 min. A double-stranded oligodeoxynucleotide containing a Myb response element (MRE) was used as a nonspeci®c competitor (Miglarese et al., 1996) . Reactions were loaded onto a 6% polyacrylamide gel and run at 100 V in 0.56 TBE buer (25 mM Tris-HCl, pH 8.5, 25 mM boric acid, 0.50 mM EDTA) at 278C. The gel was dried onto Whatman 3M paper and exposed to Re¯ection ®lm (DuPont NEN, NEF-486) at 7808C with an intensifying screen for 18 h.
Western analysis, precipitation and antibodies CHAPS lysis buer (2% CHAPS in 50 mM HEPES and 200 mM NaCl, pH 7.5, containing protease inhibitors) (Hebert et al., 1995) was used to lyse cells and to wash bead-bound precipitated material. Western blot analyses of whole cell lysates (25 mg protein/lane), immunoprecipitated products, or glutathione-S-transferase (GST)-fusion protein complexes were performed following standard procedures (Ausubel et al., 1995) , or the manufacturer's instructions (Novex, San Diego, CA or Sigma). To prevent degradation of target protein, in some experiments melanocytes were treated with the proteasome inhibitor MG132 (N-Carbobenzoxyl-Leu-Leu-Leucinal, Calbiochem, La Jolla, CA) (Coux et al., 1996) prior to harvesting. MG132 was dissolved in DMSO (100 mM stock solution/ each), and applied to the culture medium at 50 mM for the indicated time. Control dishes were incubated with equal amounts of the diluent DMSO. Equal protein loading was veri®ed by staining the gels with Coomassie brilliant blue after transfer of the proteins to membranes, or by comparison to bands resulting from blotting to another protein (CDK2 or CDK4) or to non-speci®c binding protein. The intensities of the bands were determined by scanning the ECL-X-ray ®lms with the Computing Densitometer.
Glutathione-S-transferase (GST)-pRb fusion protein, GST-pRb (379 ± 928) (Kaelin et al., 1991) (from Dr WG Kaelin, Jr., Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA) was used to demonstrate in vitro complex formation with E2F1 proteins following standard procedure (Ausubel et al., 1995) .
Antibodies to E2F1 (mAb KH95 raised against aa 342 ± 386 of human E2F1, and rabbit polyclonal C-20 against aa 418 ± 437 of human E2F1), cyclin D1 (H-295), cyclin A (C-19), p21 WAF1/CIP1 (M-19), CDK2 (M2), and CDK4 (C-22) were from Santa Cruz Biotechnology, Santa Cruz, CA; antibodies to pRb (mAb G3-245) was from PharMingen, San Diego, CA; mAb to p27 KIP1 was from Transduction Laboratories, Lexington, KY; cyclin E mAb (Ab-1) was from Calbiochem, Cambridge, MA, and rabbit polyclonal antibodies RQQ to p16 was from Dr C Sherr, Howard Hughes Medical Institute, Department Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN. Prestained molecular weight markers (Bio-Rad) were included with each Western blot and are indicated in kDa on the left hand side of the ®gures.
Detection and identi®cation of mRNAs
The expression of ectopic human E2F1 and the authenticity of the E2F1 E132 derivative in the transfected cells were analysed by RT ± PCR (reverse-transcription polymerase chain reaction) using primers speci®c to the human gene spanning the mutation site ( Table 1) . Analysis of p21 WAF1/CIP1 and control cyclophilin mRNAs was performed with quantumRNA kit (Ambion, Austin, TX) using p21 WAF1/CIP1 speci®c primer pairs (Table 1) . Total RNA (5 mg) extracted with Trizol reagent (GibcoBRL) according to the manufacturer's instructions, was primed with random hexamer and then reverse-transcribed with 25 U reverse transcriptase (MMuLV reverse transcriptase, New England BioLabs) for 1 h at 378C, followed by ampli®cation for 25 ± 30 cycles in the presence of 20 pmoles of sense-and anti-sense primers with 2.5 U of Ampli-Taq polymerase (Promega, Madison WI). Ampli®cation was carried out for 30 s at 948C, 1 min at 558C and 1 min at 728C. The reaction products were electrophoresed on a 2% agarose gel, stained with ethidium bromide and visualized with U.V. light. 
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